SI-BONE To Report First Quarter 2021 Financial Results on May 3, 2021

Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN) will report Q1 2021 financial results after market close on May 3, 2021. This announcement includes a conference call at 1:30 PM PT / 4:30 PM ET, accessible via phone or webcast on their website. The iFuse Implant System, the company's primary product for treating sacroiliac joint dysfunction, has shown positive clinical outcomes supported by multiple studies. Since 2009, iFuse has been the only SI joint fusion device with established insurance coverage based on its clinical effectiveness and safety.

Positive

• Scheduled Q1 2021 financial results report after market close on May 3, 2021.
• iFuse Implant System is supported by multiple prospective clinical studies, showing improved patient outcomes.
• Established insurance coverage for the iFuse procedure due to positive clinical data.

Negative

• None.

SANTA CLARA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2021 after market close on Monday, May 3, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 8177238. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE

SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two RCTs, showing improved pain, patient function and quality of life resulting from treatment. There are over 90 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. As well, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved. 04152021

Investor Contact:

Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

FAQ

When will SI-BONE report its Q1 2021 financial results?

SI-BONE will report its Q1 2021 financial results after market close on May 3, 2021.

What is the purpose of the conference call scheduled for May 3, 2021?

The conference call will discuss SI-BONE's Q1 2021 financial results and performance.

How can I listen to the SI-BONE conference call?

The conference call can be accessed by dialing (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 8177238.

What is the iFuse Implant System?

The iFuse Implant System is a medical device designed for sacroiliac fusion to treat joint dysfunction, with proven clinical effectiveness.